Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Check out insider trades for August 13; Bajaj Finance, Dabur, Yes Bank in focus

2018-08-17 moneycontrol
Chambal Fertilisers & Chemicals Ltd: Hindustan Times Ltd., (promoter) bought 10,000 shares through market purchase on August 13, 2018
YESBANK BAJFINANCE JAGRAN 532705 VGUARD 532648 BJJQY 538268 YYBKY WONDERLA 532953 500034

0
Check out insider trades for Aug 13; ITC, YES Bank, JSW Steel, Bajaj Finance in focus

2018-08-16 moneycontrol
JSW Steel: JSW Techno Projects Management Ltd. (promoter) bought 6,70,000 shares through market purchase from August 9 to August 10, 2018
GRUH YESBANK BAJFINANCE 500228 GRHFY 532648 BJJQY YYBKY JSWSTEEL 511288 500034

0
Check out insider trading transaction for Aug 2; YES Bank, ITC, Bajaj Finance in focus

2018-08-06 moneycontrol
Oriental Hotels Ltd: Varada Reddy Dodla bought 95,002 shares through market purchase on July 31, 2018
523648 YESBANK BAJFINANCE 500314 ORIENTHOT PLASTIBLEN 532648 BJJQY YYBKY 500034

0
Bajaj Finance Ltd. ADR 2019 Q1 - Results - Earnings Call Slides

2018-07-23 seekingalpha
The following slide deck was published by Bajaj Finance Ltd. ADR in conjunction with their 2019 Q1 earnings call.
BAJFINANCE BJJQY 500034

0
Bajaj Finance Limited - Shareholders meeting

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJFINANCE BJJQY 500034

0
Bajaj Finance soars 7% post strong Q1 show; Citi sees 22% upside on stock

2018-07-20 moneycontrol
Shares of Bajaj Finance gained 7 percent on Friday as investors cheered the company’s Q1 results.
BAJFINANCE BJJQY 500034

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 006162421